September 25, 2018Open Access

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by F. Hoffmann-La Roche/Genentech; IMpower133 ClinicalTrials.gov number, NCT02763579 .).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Horn et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69d7d52f2f3446b9d5d17ec6 — DOI: https://doi.org/10.1056/nejmoa1809064

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Authors

Leora Horn

Aaron S. Mansfield

Aleksandra Szczęsna

Journals

New England Journal of Medicine

Actions

Institutions

Chinese University of Hong Kong

Georgetown University

Centrum Onkologii

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion